Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/18 10:57:52 am
34.665 USD   +0.80%
10/11ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/27ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/22INSIDER SELL : Arcus Biosciences
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arcus Biosciences : Announces New Employment Inducement Grants

09/09/2021 | 04:11pm EDT

Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 44,200 shares of the Company’s common stock at an exercise price per share of $34.31, which was the closing price on September 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, and non-small cell lung. Quemliclustat (AB680), the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development in combination with zimberelimab and gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study evaluating zimberelimab monotherapy, domvanalimab plus zimberelimab and domvanalimab plus etrumadenant plus zimberelimab for first-line treatment of PD-L1 ≥ 50% metastatic non-small cell lung cancer (NSCLC). In addition, domvanalimab has advanced into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab and is expected to advance into a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage 3 NSCLC setting later this year. AB308, an anti-TIGIT antibody that is FcR-enabled, is in clinical development, with a potential focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences


© Business Wire 2021
All news about ARCUS BIOSCIENCES, INC.
10/11ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/27ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/22INSIDER SELL : Arcus Biosciences
MT
09/17ARCUS BIOSCIENCES : Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biolo..
PR
09/09ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/01ARCUS BIOSCIENCES : to Participate at Upcoming Investor Conferences
BU
08/24ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
08/11ARCUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/11Arcus Biosciences, Inc. Announces Board Changes
CI
08/10ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 38,8 M - -
Net income 2021 -307 M - -
Net cash 2021 555 M - -
P/E ratio 2021 -7,83x
Yield 2021 -
Capitalization 2 455 M 2 455 M -
EV / Sales 2021 49,0x
EV / Sales 2022 15,8x
Nbr of Employees 236
Free-Float 63,2%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 34,39 $
Average target price 53,90 $
Spread / Average Target 56,7%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.32.24%2 455
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414